RxDoctor Payments Data

Jamie Hicks

Primary Care · Milford, IANPI 1306843818

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.7% of the total across 49 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Mylan Specialty L.p. at 43.4% of the total.

$847in general payments, 2019–2025

Across 49 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$368
  • Exact Sciences$98
  • Phathom Pharmaceuticals, Inc.$81
  • Lilly USA, LLC$72
  • Viatris Specialty LLC$70
  • Pfizer$40
  • plus $119 from 7 others

What the payments were for

  • Food & beverage$80295%
  • Education$455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$847 in reported general payments places this provider in the 80th percentile of 36 primary care providers in Iowa.

See all primary care providers in Iowa

Medicare billing

Part B allowed, 2024
$50,917
Medicare patients
157
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$56,492
JardianceEmpagliflozin13$16,832
EliquisApixaban14$14,541
MounjaroTirzepatide11$10,338
Bydureon BciseExenatide Microspheres13$10,284
Spiriva RespimatTiotropium Bromide11$5,636
Lacosamide22$3,116
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,435
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$1,288
Rosuvastatin Calcium100$1,120
Metoprolol Succinate61$646
Duloxetine Hcl32$514
Venlafaxine Hcl ErVenlafaxine Hcl18$422
Amlodipine Besylate108$421
Losartan Potassium56$418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$14,54114 claims
Lilly USA, LLCMounjaro$72$10,33811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 36 primary care providers in Iowa.

Other primary care in Milford

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →